InvestSMART

ORDINARY FULLY PAID (ASX: OPT) - Announcements

DELISTED - Current share price for OPT : $0.013

ASX company news and announcements for ORDINARY FULLY PAID (OPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ORDINARY FULLY PAID (OPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ORDINARY FULLY PAID (OPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ORDINARY FULLY PAID (OPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Ceasing to be a substantial holder 2 Jun 2023 4:45PM $0.605 $0.013 fallen by 97.85%
$18 Opthea Presents at the Jefferies 2023 Healthcare Conference 26 May 2023 8:17AM $0.650 $0.013 fallen by 98%
$18 Opthea participates in EF Hutton hosted webinar on OPT-302 18 May 2023 8:13AM $0.630 $0.013 fallen by 97.94%
$18 Change in substantial holding 17 May 2023 6:16PM $0.630 $0.013 fallen by 97.94%
$18 Opthea Presents at JMP Securities Life Sciences Conference 9 May 2023 8:15AM $0.700 $0.013 fallen by 98.14%
$18 Opthea to Participate at HC Wainwright BioConnect Conference 28 Apr 2023 6:22PM $0.710 $0.013 fallen by 98.17%
$18 Becoming a substantial holder 20 Mar 2023 8:17PM $0.800 $0.013 fallen by 98.38%
$18 Opthea Receives A$8.7million R&D Tax Incentive 7 Mar 2023 9:17AM $0.845 $0.013 fallen by 98.46%
$18 Opthea to participate at Oppenheimer's Healthcare Conference 7 Mar 2023 8:13AM $0.845 $0.013 fallen by 98.46%
$18 Half Year Accounts 23 Feb 2023 8:35AM $0.920 $0.013 fallen by 98.59%
$18 Response to ASX Query 16 Feb 2023 4:46PM $0.920 $0.013 fallen by 98.59%
$18 Opthea Ph2b Trial Results with OPT-302 published in Journal 14 Feb 2023 8:04AM $0.935 $0.013 fallen by 98.61%
$18 Appendix 2A 10 Feb 2023 4:17PM $0.985 $0.013 fallen by 98.68%
$18 Opthea to present at SVB Leerink Global Biopharma Conference 7 Feb 2023 8:15AM $0.995 $0.013 fallen by 98.69%
$18 Opthea to Present at Sequire Biotechnology Conference 31 Jan 2023 7:41AM $0.950 $0.013 fallen by 98.63%
$18 Opthea Corporate Presentation - San Francisco Jan 2023 11 Jan 2023 8:18AM $0.880 $0.013 fallen by 98.52%
$18 Opthea Announces MST Conference call with Jason Slakter MD 13 Dec 2022 8:16AM $0.950 $0.013 fallen by 98.63%
$18 Opthea to present at the FLORetina 2022 Congress 7 Dec 2022 8:17AM $0.970 $0.013 fallen by 98.66%
$18 Cleansing Notice 30 Nov 2022 10:42AM $0.970 $0.013 fallen by 98.66%
$18 Appendix 2A 30 Nov 2022 10:39AM $0.970 $0.013 fallen by 98.66%
$18 Appendix 2A 29 Nov 2022 9:18AM $0.960 $0.013 fallen by 98.65%
$18 Cleansing Notice 29 Nov 2022 8:30AM $0.960 $0.013 fallen by 98.65%
$18 Appendix 3Y MS 29 Nov 2022 8:29AM $0.960 $0.013 fallen by 98.65%
$18 Appendix 3Y MB 29 Nov 2022 8:29AM $0.960 $0.013 fallen by 98.65%
$18 Notification regarding unquoted securities - OPT 16 Nov 2022 4:18PM $0.995 $0.013 fallen by 98.69%

251 - 275 of 733 results

Page 11 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.